New Products From Novel Drug Classes Are Addressing Key Unmet Needs for Highly Treatment-Experienced Patients, According to a New Report from Decision Resources WALTHAM, Mass., June 2
WALTHAM, Mass., June 2 /PRNewswire/ -- Decision Resources, one of the
world's leading research and advisory firms for pharmaceutical and healthcare
issues, finds that the market for HIV therapies will experience robust 5.4
percent annual growth through 2012, driven by the use of premium-priced
branded products. However, owing to the generic erosion of several key
antiretroviral drugs, market growth will slow to less than 1 percent from 2012
to 2017 in the United States, France, Germany, Italy, Spain, United Kingdom
and Japan.
The new Pharmacor report entitled HIV finds that the increasing use of
Bristol-Myers Squibb/Gilead's Atripla, Gilead/Japan Tobacco's Truvada and
Bristol-Myers Squibb's Reyataz in early lines of therapy, coupled with
continuing uptake of Johnson & Johnson's Prezista, Merck's Isentress and
Pfizer's Selzentry in highly treatment-experienced patients will fuel the
near-term growth in the HIV market. The use of Prezista and Isentress is
expected to increase once their labels expand to include treatment initiation
in asymptomatic patients.
Based on the drug's efficacy and safety profile demonstrated in clinical
trials to date, interviewed thought leaders perceive Johnson & Johnson's
rilpivirine as the most promising HIV agent in late stages of development,
according to the report. Additionally, new market entrants from Merck and
Pfizer from the integrase inhibitors and CCR5 antagonist classes,
respectively, are providing highly treatment-experienced patients with greatly
needed additional therapeutic options.
"The increasingly wider use of premium-priced marketed products such as
Atripla, Truvada, and Reyataz in early lines of therapy will be the major
growth driver of the HIV market over the next decade," said Sylvia Eash,
Ph.D., analyst at Decision Resources. "These antiretroviral agents will
continue to be dominate players in this market with forecasted sales,
combined, of more than $5 billion in 2017."
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market
research publications, advisory services, and consulting designed to help
clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
For more information, contact:
Elizabeth Marshall
Decision Resources, Inc.
781-296-2563
emarshall@dresources.com
SOURCE Decision Resources
